Jeb Bush Wasn’t Bashful About Trading on Family Name
While Jeb Bush frequently is touted as both a two-term governor and a successful businessman, his often dubious record as an entrepreneur and investor has been widely documented over the past three decades.
The 62-year-old scion of a powerful political family and now an announced candidate for the 2016 GOP presidential nomination was involved in a myriad business ventures dating back to the mid-1980s, The Washington Post noted on Monday in the latest media examination of Bush’s entrepreneurial exploits as he tried to amass his fortune.
Related: Jeb Bush Shows Some Fire in Campaign Launch
Bush brokered numerous real estate deals in Miami, helped to arrange bank loans in Venezuela, marketed shoes in Panama, sought out Mexican investors for a building-materials company, advised transnational financial services firms — you name it. He also made a boatload of money by sitting on a handful of corporate boards. And ever since he left the Florida governor’s office in 2007, Bush — like Democrat Hillary Clinton — has raked in substantial income by giving speeches while also consulting and managing investments for others.
“Jeb Bush had a successful career in commercial real estate and business before serving as Florida’s governor,” Kristy Campbell, a spokeswoman for Bush, told the Post. “He has always operated with the highest level of integrity throughout his business career.”
And yet the Post’s lengthy review of Bush’s business career — culled from records, lawsuits, interviews and newspapers accounts dating back more than 30 years — reveals a picture of a young man on the make who “often benefited from his family connections and repeatedly put himself in situations that raised questions about his judgement and exposed him to reputational risks.”
Related: Can Jeb Bush Unite the GOP’s Establishment and Religious Wings?
Five of Bush’s former business associates have been convicted of crimes; one remains an international fugitive on fraud charges. Bush has disavowed any knowledge of the wrongdoing and conceded that some of the businessmen he met in Florida took advantage of his relative youth and naiveté.
One thing that comes through loud and clear in the Post report is that Jeb Bush had no compunction about trading on his family name in trying to make a buck.
Major case in point: In early 1989, seven weeks after his father, George H.W. Bush, took office as president, Jeb Bush took a trip to Nigeria with the executive of a Florida company called Moving Water Industries. Bush had just been hired to help market the firm’s water pumps.
With no less than a special escort from the U.S. ambassador to Nigeria, Bush and his new boss met with the nation’s political and religious leaders as part of the company’s effort to land a deal that would be worth $80 million.
“My father is the president of the United States, duly elected by people that have an interest in improving ties everywhere,” the young Bush told the group. “The fact that you have done this today is something I will report back to him very quickly when I get back to the United States.”
Just days after Bush returned to the U.S., his father sent the president of Nigeria a handwritten note thanking him for hosting his son. Not surprisingly, Moving Water Industries eventually landed the deals it was seeking, according to the Post.
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.